<!DOCTYPE html><html xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd">
<head>
<meta http-equiv="default-style" content="text/html; charset=utf-8" />
<title>Campbell-Walsh-Wein Urology Twelfth Edition Review</title>
<link rel="stylesheet" type="text/css" href="../../style/Elsevier_eBook.css" />
<link rel="stylesheet" type="text/css" media="only screen" href="../../style/media.css" />
  

<link rel="stylesheet" type="text/css" href="../../widgets/common_assets/css/common.css" />
<link rel="stylesheet" type="text/css" href="../../widgets/common_assets/css/variables.css" />
<script type="text/javascript" src="../../widgets/common_assets/scripts/mathjax/tex-mml-chtml.js"></script>
<script type="text/javascript" src="../../widgets/common_assets/scripts/common.js"></script>
</head>
<body>
<section epub:type="chapter">
<a id="c0160"></a>
<header>
<div id="CN">160</div>
<h1 class="chaptitle" epub:type="title" id="B9780323639699001609">Management Strategies for Biochemical Recurrence of Prostate Cancer</h1>
<address>
<div class="chapau" id="augrp0010">Eugene K. Lee, and J. Brantley Thrasher</div>
</address>
</header>
<section>
<h3 class="h2hd" id="cesectitle0010">Keywords</h3>
<div class="keywords">biochemical recurrence; prostate cancer imaging; prostate cancer; salvage cryotherapy; salvage prostatectomy; salvage radiation</div>
</section>
<section>
<section>
<a id="s0010"></a>
<div>
<iframe src="../../widgets/MCMS/xhtml/ch160_assessments.xhtml" height="650"></iframe>
</div>
<div>

<div class="boxg1" id="b0010">
<p></p>
<div class="b1title" epub:type="title" id="title5050">Chapter Review</div>
<div id="bpar0010"></div>
<div>
<ul class="ce_list" id="olist0055">
<li class="b1numlist" id="bpar0015">
<a id="o0225"></a>1. The AUA and the EAU have defined biochemical recurrence following radical prostatectomy as a value of ≥0.2 ng/mL with a second confirmatory value.</li>
<li class="b1numlist" id="bpar0020">
<a id="o0230"></a>2. Salvage radiation therapy should be discussed with patients with non-metastatic prostate cancer and a rising PSA following radical prostatectomy.</li>
<li class="b1numlist" id="bpar0025">
<a id="o0235"></a>3. Androgen deprivation therapy should be considered in patients receiving salvage radiation therapy, especially in those with high-risk features.</li>
<li class="b1numlist" id="bpar0030">
<a id="o0240"></a>4. Multiparametric MRI can be a useful tool for detection of local recurrence following radical prostatectomy.</li>
<li class="b1numlist" id="bpar0035">
<a id="o0245"></a>5. Patients who undergo a transient rise in their PSA should be closely monitored, because not all men are destined for biochemical failure, let alone clinical failure.</li>
<li class="b1numlist" id="bpar0040">
<a id="o0250"></a>6. The ideal candidates for salvage radical prostatectomy have at least 10 years of life expectancy, lack of metastasis on imaging, and a PSA less than 10 ng/mL.</li>
</ul>
</div>
</div>
</div>
</section>
<footer>
<section epub:type="footnotes">
<div class="ftnote">
<hr />
<p class="ftnote1" id="fn1" epub:type="footnote">
<sup>
<a href="#cfn1">a</a><span id="cfn1"></span>
</sup> <a id="ntpara0010"></a>Sources referenced can be found in <span class="italic">Campbell-Walsh Urology, 12th Edition,</span> on the Expert Consult website.</p>
</div>
</section>
</footer>
</section>
</section><span id="s0015"></span><span id="pagebreak_610"></span>
</body>
</html>
